v3.24.0.1
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net revenues $ 54,318 $ 58,054 $ 56,197
Cost of products sold 20,415 17,414 17,446
Selling, general and administrative 12,872 15,260 12,349
Research and development 7,675 6,510 6,922
Acquired IPR&D and milestones 778 697 1,124
Other operating expense (income), net (179) 56 432
Total operating costs and expenses 41,561 39,937 38,273
Operating earnings 12,757 18,117 17,924
Interest expense, net 1,684 2,044 2,384
Net foreign exchange loss 146 148 51
Other expense, net 4,677 2,448 2,500
Earnings before income tax expense 6,250 13,477 12,989
Income tax expense 1,377 1,632 1,440
Net earnings 4,873 11,845 11,549
Net earnings attributable to noncontrolling interest 10 9 7
Net earnings attributable to AbbVie Inc. $ 4,863 $ 11,836 $ 11,542
Per share data      
Basic earnings per share (in dollars per share) $ 2.73 $ 6.65 $ 6.48
Diluted earnings per share (in dollars per share) $ 2.72 $ 6.63 $ 6.45
Weighted-average basic shares outstanding (in shares) 1,768 1,771 1,770
Weighted-average diluted shares outstanding (in shares) 1,773 1,778 1,777